Protalix BioTherapeutics
PLX
26 hedge funds and large institutions have $4.87M invested in Protalix BioTherapeutics in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 4 closing their positions.
1,030% more call options, than puts
Call options by funds: $1.41M | Put options by funds: $125K
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
32% more capital invested
Capital invested by funds: $3.7M → $4.87M (+$1.17M)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0.09% less ownership
Funds ownership: 7.13% → 7.04% (-0.09%)
4% less funds holding
Funds holding: 27 → 26 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$118K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$72.1K |
| 3 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$55K |
| 4 |
CIBC World Market
Toronto,
Ontario, Canada
|
+$39.5K |
| 5 |
Jane Street
New York
|
+$15.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$244K |
| 2 |
DC
Davenport & Co
Richmond,
Virginia
|
-$23K |
| 3 |
ACA
Aptus Capital Advisors
Fairhope,
Alabama
|
-$15K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$12.1K |
| 5 |
Two Sigma Advisers
New York
|
-$5.16K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
UBS Group
Zurich,
Switzerland
| $164 | -$12.1K | -10,998 | -99% |
|
|
27
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$244K | -222,261 | Closed |
|
|
DC
28
Davenport & Co
Richmond,
Virginia
| – | -$23K | -22,000 | Closed |
|
|
ACA
29
Aptus Capital Advisors
Fairhope,
Alabama
| – | -$15K | -13,957 | Closed |
|
PLX Hedge Fund Activity: Q4 2022 in Review
26 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q4 2022, worth a combined $4.87M — up 32% from $3.7M a quarter earlier.
Fund positioning in PLX was balanced in Q4 2022: 4 funds opened new positions, 4 closed out, 7 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $118K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $244K sold.
- 26 institutional investors held Protalix BioTherapeutics (PLX) as of Q4 2022, down from 27 in Q3 2022.
- Funds reported $4.87M of Protalix BioTherapeutics stock for Q4 2022, up 32% quarter-over-quarter.
- 4 funds opened new Protalix BioTherapeutics positions in Q4 2022 and 4 closed out, a net change of 0 holders.
- The largest Protalix BioTherapeutics buyer in Q4 2022 was Renaissance Technologies, an estimated $118K added.
- The largest Protalix BioTherapeutics seller in Q4 2022 was Susquehanna International Group, an estimated $244K sold.
Based on aggregated 13F filings for Q4 2022.